萬隆控股集團(00030.HK)與雲南研究所達成戰略合作 專注於工業大麻相關產品研發
格隆匯2月15日丨萬隆控股集團(00030.HK)公佈,於2022年2月15日,公司與雲南研究所(雲南白藥集團全資擁有之獨立法人實體)訂立該協議,據此,公司與雲南研究所建立戰略合作關係,以專注於工業大麻相關產品之研發,發揮雙方之資源優勢以促成長遠合作。
經妥為考慮雲南研究所的能力後,董事認為,該協議及據此擬進行之交易為集團提供良機,可藉助雲南研究所之專業知識從事有關工業大麻及相關領域的研發,並通過與雲南研究所建立長期、穩定之合作關係以進一步發展其大麻培植及種植業務,可促進集團的長遠業務增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.